A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women

Trial Profile

A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Papillomavirus vaccines (Primary)
  • Indications Adenocarcinoma; Cervical cancer; Cervical intraepithelial neoplasia; Papilloma
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 19 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 16 Feb 2016 Planned End Date changed from 1 May 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.
    • 16 Feb 2016 Planned primary completion date changed from 1 May 2016 to 1 Aug 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top